Valuation: Unicycive Therapeutics, Inc.

Market Cap 148M 130M 121M 111M 208M 14.25B 212M 1.43B 561M 7B 555M 543M 24.21B P/E 2026 *
-3.82x
P/E 2027 * 1.05x
Enterprise Value 148M 130M 121M 111M 208M 14.25B 212M 1.43B 561M 7B 555M 543M 24.21B EV / Sales 2026 *
38.9x
EV / Sales 2027 * 0.51x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * 42.6%
1 day-4.35%
1 week-4.95%
Current month+10.45%
1 month-32.73%
3 months-28.35%
6 months-28.06%
Current year-10.23%
1 week 5.15
Extreme 5.1501
5.87
1 month 3.93
Extreme 3.93
8.05
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
36.2
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 17/08/2016
Director of Finance/CFO 64 28/02/2021
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Chairman 53 17/08/2016
Director/Board Member 58 31/12/2017
Director/Board Member 58 05/09/2023
Date Insider Type Main position Quantity % Market Cap.
14/05/26 Free

Chief Executive Officer

762,200 3.0201%
14/05/26 Free

Executive/Senior Manager

169,500 0.6716%
14/05/26 Free

Director

126,300 0.5004%
Change 5-day change 1-year change 3-year change Capi.($)
-4.26%-4.95%+9.98%-56.10% 148M
-1.82%+4.80%+54.32%+68.36% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-0.51%-1.33%+3.78%+417.65% 23.18B
+2.33%-0.88%-19.01%-13.00% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+3.30%+27.41%-29.07% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+1.18%+0.83%+26.13%+185.66% 13.92B
Average +0.23%+1.49%+38.93%+154.34% 24.02B
Weighted average by Cap. +0.07%+1.93%+39.86%+138.50%

Financials

2026 *2027 *
Net sales 3.8M 3.34M 3.11M 2.85M 5.36M 366M 5.44M 36.9M 14.42M 180M 14.28M 13.97M 623M 288M 253M 236M 216M 406M 27.77B 412M 2.8B 1.09B 13.65B 1.08B 1.06B 47.21B
Net income -40.34M -35.43M -32.95M -30.23M -56.81M -3.88B -57.68M -391M -153M -1.91B -151M -148M -6.6B 186M 164M 152M 140M 262M 17.93B 266M 1.81B 706M 8.82B 699M 684M 30.48B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
27/07/26 US$5.185 -3.98% 312,375
24/07/26 US$5.400 -1.10% 497,709
23/07/26 US$5.460 -1.97% 649,585
22/07/26 US$5.570 -2.11% 595,078
21/07/26 US$5.690 +4.40% 1,139,169
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.400USD
Average target price
38.59USD
Spread / Average Target
+614.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock